Immunocore Holdings plc balance sheet IMCR

Annual Quarterly

As of Jun 30, 2026, Immunocore Holdings plc had total assets of $1.1 billion and total liabilities of $699.6 million. Total assets were up 3.4% from a year earlier. Stockholders' equity was $419.8 million. It held $880.2 million in cash and investments against $40.8 million of total debt, net cash of $839.5 million. The current ratio, current assets divided by current liabilities, was 4.47.

USD in millions, except ratios and per-share amounts. The percent under a figure is the change from the same quarter a year earlier.

Line	Q2 FY2026 Jun 30, 2026	Q1 FY2026 Mar 31, 2026	Q4 FY2025 Dec 31, 2025	Q3 FY2025 Sep 30, 2025	Q2 FY2025 Jun 30, 2025	Q1 FY2025 Mar 31, 2025	Q4 FY2024 Dec 31, 2024	Q3 FY2024 Sep 30, 2024
Assets
Cash	485 -0.6%	453 -5.1%	468 +2.6%	498 -7.3%	488 -3.4%	477 -42.7%	456 +3.0%	538
Short-term investments	395 +0.1%	392 +8.9%	396 +8.7%	394 +8.4%	395 +11.4%	360	365	364
Cash and investments	880 -0.3%	845 +0.9%	864 +5.3%	892 -1.0%	883 +2.7%	837 +0.5%	820 +85.3%	901
Receivables	—	—	—	—	—	—	63 +21.0%	64
Inventory	8 +42.8%	8 +21.3%	7 +23.8%	6 +25.2%	5 +57.6%	7 +63.3%	5 +21.0%	5
Total current assets	1,051 +4.9%	1,004 +5.8%	997 +7.2%	1,023 +1.7%	1,002 +4.7%	949 +2.4%	930 +75.8%	1,006
Property and equipment, net	13 +34.7%	12 +24.1%	11 +13.6%	9 +3.0%	10 +24.3%	10 +16.6%	10 +9.5%	9
Total assets	1,119 +3.4%	1,072 +4.3%	1,067 +5.7%	1,102 +1.6%	1,082 +5.8%	1,028 +3.4%	1,010 +69.1%	1,085
Liabilities and equity
Accounts payable	26 +10.3%	30 +3.6%	24 -2.9%	23 +16.4%	24 +19.6%	29 +87.8%	25 +41.0%	20
Total current liabilities	235 +38.3%	240 +61.0%	247 +16.3%	170 -36.0%	170 -8.1%	149 -3.9%	212 +52.6%	266
Total liabilities	700 +0.8%	678 +4.4%	686 +5.8%	706 -0.1%	694 +4.5%	650 +2.4%	649 +184.4%	707
Stockholders' equity	420 +8.1%	394 +4.0%	381 +5.6%	397 +5.0%	388 +8.2%	378 +5.3%	361 -2.2%	378
Debt
Long-term debt	—	—	—	—	—	—	—	439
Lease liabilities	41 -8.2%	42 -1.0%	44 +4.4%	43 +2.1%	44 +27.5%	42 +20.5%	42 +15.8%	42
Total debt	41 -8.2%	42 -1.0%	44 +4.4%	43 -91.0%	44 -90.9%	42 -91.3%	42 +15.8%	481
Net cash	839 +0.1%	803 +1.0%	821 +5.4%	849 +102.1%	838 +125.2%	795 +130.2%	779 +91.5%	420
Ratios
Current ratio	4.47x	4.18x	4.04x	6.00x	5.89x	6.36x	4.38x	3.78x
Debt to equity	0.10x	0.11x	0.11x	0.11x	0.11x	0.11x	0.12x	1.27x
Return on equity	-4.31%	-7.00%	-9.32%	-7.37%	-5.23%	-5.71%	-14.16%	—
Return on assets	-1.61%	-2.57%	-3.33%	-2.65%	-1.88%	-2.10%	-5.06%	—
Book value per share	8.15	7.74	7.52	7.86	7.71	7.54	7.20	7.55

How these figures are calculated

Quarterly columns are single-quarter amounts. When a 10-Q reports only a year-to-date total, as cash flow statements do, the quarter is that total minus the previous quarter's year-to-date total. The fourth quarter is the annual report's full year minus the first nine months. A column marked YTD is a year-to-date total, shown when the earlier report needed for the single quarter is missing. USD in millions, except ratios and per-share amounts. Cash and investments adds short-term and long-term marketable securities to cash. Debt due within a year is the borrowings that are not already in long-term debt. Total debt is those borrowings plus lease liabilities. Net cash is cash and investments minus total debt. Return on equity and return on assets divide the trailing twelve months of net income by the balance on that date. Debt to EBITDA uses the trailing twelve months of EBITDA. More on our methodology.

Company profile

Industry: Biological Products, (No Diagnostic Substances) (SIC 2836)
Listed as: IMCR (Nasdaq)
Fiscal year ends: December 31
Incorporated in: United Kingdom
Headquarters: Oxfordshire, United Kingdom
SEC filer status: Large accelerated filer
SEC CIK: 1671927
Former names: Immunocore Ltd (until Feb 1, 2021)

Other Biological Products, (No Diagnostic Substances) companies

All 182 Biological Products, (No Diagnostic Substances) companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.